This is the authors' abstract. We don't add key points for this paper.
Despite the limitations due to the use of ITC and the comparison between clinical trials and real-world cohorts, the present analysis suggests potential benefits in terms of vision gain and CST reduction in naïve nAMD patients treated with faricimab compared with SoC in a real-world setting.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Galeone et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: